格卡瑞韦/匹仑他韦治疗肝或肾移植合并丙型肝炎病毒感染患者
MAGELLAN-2 是一项 3 期开放标签试验,纳入肝移植 80 例、肾移植 20 例慢性 HCV GT1-6 感染患者,接受格卡瑞韦/匹仑他韦 300/120 mg 每日一次治疗 12 周。总体 SVR12 为 98%(98/100,95%CI 95.3%-100%),超过预设历史标准治疗 SVR12 阈值 94%,不良事件多为轻度。
要点
- 肝或肾移植后慢性 HCV GT1-6 感染患者接受格卡瑞韦/匹仑他韦 12 周,总体 SVR12 达 98%。
- SVR12 超过预设历史标准治疗阈值 94%,1 例患者出现病毒学失败。
- 不良事件多为轻度,实验室异常不常见,1 例因不良事件停药(判定与治疗无关)且仍达 SVR12。
核心结论
- 每日一次格卡瑞韦/匹仑他韦治疗 12 周是一种耐受性良好且有效的无利巴韦林方案,适用于接受肝或肾移植的慢性 HCV GT1-6 感染患者。
研究设计与样本
- MAGELLAN-2 为 3 期开放标签试验,纳入移植后≥3 个月的肝移植 80 例和肾移植 20 例患者,共 100 例。
- 无肝硬化且 HCV 初治(GT1-6)或经治(GT1、2、4-6;接受含干扰素方案联合或不联合索磷布韦,或索磷布韦联合利巴韦林)的患者接受格卡瑞韦/匹仑他韦 300/120 mg 每日一次治疗 12 周。
主要发现
- 80% 患者纤维化评分为 F0-F1,HCV GT1 占 57%、GT3 占 24%。
- 总体 SVR12 为 98%(98/100;95%CI 95.3%-100%),超过预设历史标准治疗 SVR12 阈值 94%。
- 1 例患者出现病毒学失败;1 例因不良事件停药(判定与治疗无关),该患者仍达 SVR12。
- 不良事件多为轻度,实验室异常不常见。
关键数值与推荐
- 主要终点为格卡瑞韦/匹仑他韦组 SVR12 百分比与基于标准治疗的历史 SVR12 率比较,预设历史标准治疗 SVR12 阈值为 94%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Well-tolerated, ribavirin-free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority. Once-daily glecaprevir/pibrentasvir demonstrates high rates of sustained virologic response at 12 weeks posttreatment (SVR12) across all major HCV genotypes (GTs). This trial evaluated the safety and efficacy of glecaprevir/pibrentasvir for patients with chronic HCV GT1-6 infection who had received a liver or kidney transplant. MAGELLAN-2 was a phase 3, open-label trial conducted in patients who were ≥3 months posttransplant. Patients without cirrhosis who were HCV treatment-naive (GT1-6) or treatment-experienced (GT1, 2, 4-6; with interferon-based therapy with or without sofosbuvir, or sofosbuvir plus ribavirin) received glecaprevir/pibrentasvir (300/120 mg) once daily for 12 weeks. The primary endpoint compared the percentage of patients receiving glecaprevir/pibrentasvir with SVR12 to a historic SVR12 rate based on the standard of care. Safety of glecaprevir/pibrentasvir was assessed. In total, 80 liver transplant and 20 kidney transplant patients participated in the trial. Most patients had no or minimal fibrosis (80% had fibrosis scores F0-F1) and were infected with HCV GT1 (57%) or GT3 (24%). The overall SVR12 was 98% (n/N = 98/100; 95% confidence interval, 95.3%-100%), which exceeded the prespecified historic standard-of-care SVR12 threshold of 94%. One patient experienced virologic failure. One patient discontinued because of an adverse event considered to be unrelated to treatment; this patient achieved SVR12. Adverse events were mostly mild in severity, and laboratory abnormalities were infrequent. CONCLUSION: Once-daily glecaprevir/pibrentasvir for 12 weeks is a well-tolerated and efficacious, ribavirin-free treatment for patients with chronic HCV GT1-6 infection who have received a liver or kidney transplant. (ClinicalTrials.gov NCT02692703.) (Hepatology 2018; 00:000-000).
引用
- Reau N, Kwo PY, Rhee S, et al. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018. PMID: 29672891. doi:10.1002/hep.30046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。